In June 2022, we entered into the ATM Agreement with Wainwright, which was amended on September 1, 2022, pursuant to which we may offer and sell, from time to time through Wainwright, shares of our c…
Research and development expenses consist primarily of fees paid to contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, as well as compensation expenses for c…
Research and development expenses consist primarily of fees paid to contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, as well as compensation expenses for c…
On December 22, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares …
he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock
Indaptus Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INDP-DEBT-10278
Warrants outstanding: 1788729
90%
xbrl warrant detail from xbrl 2026-03-31.
INDP-DEBT-10279
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Indaptus Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Indaptus Therapeutics, Inc..
Indaptus Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
INDP-OWNER-DANSKE-BANK-A-S
DANSKE BANK A/S
90%
13F overlay lists DANSKE BANK A/S as top holder; 1 tracked holders.
Indaptus Therapeutics, Inc. Extended Supply Chain Network
